HK1210424A1 - 激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途 - Google Patents

激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途

Info

Publication number
HK1210424A1
HK1210424A1 HK15111246.2A HK15111246A HK1210424A1 HK 1210424 A1 HK1210424 A1 HK 1210424A1 HK 15111246 A HK15111246 A HK 15111246A HK 1210424 A1 HK1210424 A1 HK 1210424A1
Authority
HK
Hong Kong
Prior art keywords
glpir
glp1r
metformin
agonist
diabetes
Prior art date
Application number
HK15111246.2A
Other languages
English (en)
Inventor
.米賈裡
.克拉克
.波裡塞蒂
.小奎達
.瓦爾卡西洛佩茲
.安德魯斯
.戴維斯
.約庫姆
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of HK1210424A1 publication Critical patent/HK1210424A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24Y being a hetero atom
    • C07C279/26X and Y being nitrogen atoms, i.e. biguanides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15111246.2A 2013-01-17 2015-11-13 激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途 HK1210424A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361753567P 2013-01-17 2013-01-17
PCT/US2014/011394 WO2014113357A1 (en) 2013-01-17 2014-01-14 Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Publications (1)

Publication Number Publication Date
HK1210424A1 true HK1210424A1 (zh) 2016-04-22

Family

ID=50030537

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111246.2A HK1210424A1 (zh) 2013-01-17 2015-11-13 激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途

Country Status (14)

Country Link
US (1) US20150313908A1 (zh)
EP (1) EP2945618B1 (zh)
JP (1) JP6445459B2 (zh)
KR (1) KR102165434B1 (zh)
CN (1) CN104968341B (zh)
AU (1) AU2014207748B2 (zh)
CA (1) CA2896308C (zh)
EA (1) EA201591123A1 (zh)
ES (1) ES2687083T3 (zh)
HK (1) HK1210424A1 (zh)
IL (1) IL239714A0 (zh)
MX (1) MX366685B (zh)
SG (2) SG10201704716XA (zh)
WO (1) WO2014113357A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060653A1 (en) 2017-09-22 2019-03-28 Regeneron Pharmaceuticals, Inc. GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF
KR20210005843A (ko) * 2018-05-08 2021-01-15 브이티브이 테라퓨틱스 엘엘씨 Glp1r 작용제의 치료적 용도
JP2023528726A (ja) * 2020-04-01 2023-07-06 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー.,エルティーディー. Glp1rアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法
EP4130005A4 (en) * 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd CRYSTALLINE FORM A OF GLP-1 RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
US20090221652A1 (en) * 2005-11-07 2009-09-03 Geesaman Bard J Combinations of metformin and meglitinide
EA018225B1 (ru) * 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
EA023430B1 (ru) * 2009-03-30 2016-06-30 виТиви ТЕРАПЬЮТИКС ЭлЭлСи Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
WO2011031620A1 (en) 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
TR201809460T4 (tr) * 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20130040878A1 (en) * 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients

Also Published As

Publication number Publication date
JP2016505039A (ja) 2016-02-18
CN104968341B (zh) 2020-06-09
WO2014113357A1 (en) 2014-07-24
EA201591123A1 (ru) 2015-11-30
KR20150104572A (ko) 2015-09-15
KR102165434B1 (ko) 2020-10-14
SG10201704716XA (en) 2017-07-28
JP6445459B2 (ja) 2018-12-26
EP2945618A1 (en) 2015-11-25
AU2014207748A1 (en) 2015-07-09
CA2896308A1 (en) 2014-07-24
MX366685B (es) 2019-07-19
MX2015008555A (es) 2016-01-22
EP2945618B1 (en) 2018-06-13
CN104968341A (zh) 2015-10-07
SG11201504778UA (en) 2015-07-30
AU2014207748B2 (en) 2018-10-11
US20150313908A1 (en) 2015-11-05
CA2896308C (en) 2021-11-09
ES2687083T3 (es) 2018-10-23
IL239714A0 (en) 2015-08-31

Similar Documents

Publication Publication Date Title
HRP20181296T1 (hr) Novi spojevi za suzbijanje člankonožaca
HRP20190528T1 (hr) PROCJENA, TESTOVI I LIJEČENJE POREMEĆAJA POSREDOVANIH S pKAL
HK1226084A1 (zh) 用於治療糖尿病的gip和glp-1受體雙重激動劑
IL240285A0 (en) Biomarkers for type ii diabetes and their uses
PT3811943T (pt) Composto para uso no tratamento de distúrbios oculares
PL3046470T3 (pl) Diagnozowanie i leczenie zaburzeń ruchu
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
IL243572A0 (en) Drug combination for the treatment of melanoma
HK1207860A1 (zh) 用於治療糖尿病及其相關病症的 -苯基- -雜環基-四氫- -吡喃- -胺化合物
GB2519982B (en) Fungicidal composition and the use thereof
HK1210424A1 (zh) 激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
IL241474B (en) A device with joints for the wrist
PT3041441T (pt) Ortótese da mão para suportar o polegar, em particular nos casos de rizartrose
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders
EP3713604C0 (de) Verbindung zur anwendung bei der steigerung von mentaler leistungsfähigkeit
GB201800645D0 (en) Monitoring medication consumption
GB201314183D0 (en) Status of type 2 diabetes
GB201304197D0 (en) Thumb pad embodiments
TWM476976U (en) Wrist pad
GB201320349D0 (en) New therapeutic use
TWM476582U (en) Watch type stethoscope device
GB201303232D0 (en) Tramadol for the mouth